52 33 u00b1 9 87 173 3932 u03bcm ngf 17 8 ng ml 55 04 u00b1 11 29 182 37100 u03bcm ngf 17 8 ng ml 83 13 u00b1 5 35 275 45______________________________________ the compounds of formulas a and b or a pharmaceutically acceptable salt thereof would be administered to a patient in need of treatment either orally or parenterally the amount of compound to be administered would depend in part on the age weight and general condition of the patient typically a patient would be closely monitored by a physician who could determine if the dosage amount or regimen of compound being administered was effective and well tolerated the compounds of formulas a and b or salts thereof would be administered admixed with a pharmaceutically acceptable carrier an effective unit dose of the compounds would be from 0 083 to 1 67 mg kg of body weight of the patient with a daily dose ranging from 1 66 to 3 34 mg kg of body weight of the patient for preparing pharmaceutical compositions from the compounds of this invention inert pharmaceutically acceptable carriers can be either solid or liquid solid form preparations include powders tablets dispersible granules capsules cachets and suppositories a solid carrier can be one or more substances which may also act is diluents flavoring agents solubilizers lubricants suspending agents binders or tablet disintegrating agents it can also be an encapsulating material in powders the carrier is a finely divided solid which is in a mixture with the finely divided active component in tablets.